IDEAYA's darovasertib plus crizotinib shows efficacy in HLA-A2 negative uveal melanoma

IDEAYA Biosciences announced primary results from the OptimUM-02 trial evaluating darovasertib combined with crizotinib as first-line treatment for HLA-A2 negative metastatic uveal melanoma patients. The trial addresses an unmet medical need in a patient population with no current FDA-approved treatment options.